Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 10:17 PM
Ignite Modification Date:
2025-12-26 @ 10:17 PM
NCT ID:
NCT00216112
Eligibility Criteria:
Inclusion Criteria:
* Histologically documented diagnosis of ovarian cancer, primary peritoneal carcinomatosis or fallopian tube cancer·
* Immunohistochemical documentation of c-Kit or PDGFR expression by tumor
* At least one measurable site of disease as defined by RECIST or evidence of disease progression by CA125 measurement
* Platinum-refractory or platinum-resistant
Exclusion Criteria:
* No prior exposure to imatinib (Gleevec®) as single agent or in combination
* No chemotherapy within 28 days (42 days for nitrosourea or mitomycin-C) prior to being registered to protocol therapy.
* No prior radiotherapy to ³ 25 % of the bone marrow
* No known brain metastases.
* Negative pregnancy test
* No current breastfeeding
* No investigational agents within 28 days prior to protocol therapy
* No prior malignancy in the past 5 years unless the other primary malignancy is not currently clinically significant, nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ
* No severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection)
* No known diagnosis of human immunodeficiency virus (HIV) infection.
* No major surgery within 28 days prior to being registered to protocol therapy.
* No refractory ascites requiring drainage more frequently than once a month
* No presence of clinically significant small bowel obstruction
* No prior exposure to docetaxel (exposure to paclitaxel is allowed)
* No parenteral nutrition within 28 days prior to being registered to protocol therapy.
* No concomitant treatment with potent CYP 3A4 inhibitors (i.e., ketoconazole) is permitted during therapy on this protocol.
* No therapeutic anticoagulation with warfarin while on study (use of low molecular weight heparin is allowed, if necessary).
* No peripheral neuropathy \> grade 1
* No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.
* No serious concomitant systemic disorders incompatible with the study
* No prior malignancies with the exception of curatively treated basal or squamous carcinoma of the skin, carcinoma in-situ of the cervix, or any other cancer for which the patient has been disease-free for \< 5 years.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT00216112
Study Brief:
Protocol Section:
NCT00216112